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Proteasome inhibition is highly effective as a treat-
ment for multiple myeloma, and recently carfilzomib
was granted US FDA approval for the treatment of
relapsed and refractory multiple myeloma. Here, we
report the X-ray crystal structure of the human
constitutive 20S proteasome with and without carfil-
zomib bound at 2.9 and 2.6 A˚, respectively. Our data
indicate that the S3 and S4 binding pockets play a
pivotal role in carfilzomib’s selectivity for chymo-
trypsin-like sites. Structural comparison with the
mouse immunoproteasome crystal structure reveals
amino acid substitutions that explain carfilzomib’s
slight preference for chymotrypsin-like subunits of
constitutive proteasomes. In addition, comparison
of the human proteasome:carfilzomib complex with
the mouse proteasome:PR-957 complex reveals
new details that explain why PR-957 is selective for
immunoproteasomes. Together, the data presented
here support the design of inhibitors for either consti-
tutive or immunoproteasomes, with implications for
the treatment of cancers as well as autoimmune
and neurodegenerative diseases.
INTRODUCTION
The proteasome degrades the majority of intracellular proteins
and plays a critical role in cellular homeostasis. In eukaryotic
cells, products of the ubiquitin proteasome pathway play roles
in antigen processing, cell differentiation, signal transduction,
and apoptosis (Voges et al., 1999; Voorhees et al., 2003). The
26S proteasome is at the heart of the ubiquitin proteasome
pathway and consists of a catalytic 20S core particle and an
ATP-dependent 19S cap, or regulatory particle, which recog-
nizes and unfolds proteins that have been tagged for degrada-
tion with a string of at least five ubiquitin molecules. Eukaryotic
proteasomes consist of 28 protein subunits and are organized
as four stacked rings of seven subunits each. There are seven
distinct a and seven distinct b chains, and the proteasome is
arranged as a1-7b1-7b1-7a1-7, resulting in C2 symmetry. The b
chains contain a total of six catalytic sites with three distinct
substrate specificities: caspase-like (b1), trypsin-like (b2), and
chymotrypsin-like (b5) (Kisselev et al., 1999). All active sites418 Structure 23, 418–424, February 3, 2015 ª2015 Elsevier Ltd All rcontain an N-terminal threonine, which acts as a nucleophile in
peptide bond hydrolysis, making the proteasome a member of
the N-terminal nucleophile hydrolases superfamily (Brannigan
et al., 1995).
There are three forms of the 20S core particle in jawed verte-
brates: the constitutive proteasome, the immunoproteasome,
and the thymoproteasome (Groettrup et al., 2010; Murata
et al., 2007). During infection, T cells release cytokines such as
tumor necrosis factor a and interferon-g, which induce the
expression of the immunoproteasome b subunits, designated
b1i/LMP2, b5i/LMP7, and b2i/MECL-1, which replace their
constitutive counterparts while the other subunits remain un-
changed (Griffin et al., 1998; Groettrup et al., 1996). Positive
selection of developing T cells, on the other hand, is controlled
by the thymoproteosome, which is expressed solely in cortical
thymic epithelial cells (Nitta et al., 2010).
Actively proliferating cells, such as cancer cells, are especially
susceptible to inhibition of the constitutive proteosome and
immunoproteasome because of the dependence on the regula-
tory/signaling mechanisms for control of the cell cycle (Chauhan
et al., 2005; Jullig et al., 2006). Inactivation of the chymotrypsin-
like active sites, b5/b5i, has long been considered to be most
detrimental to cell survival, and themajority of proteasome inhib-
itors are designed to target these sites.
Recently, the epoxomicin analog carfilzomib (Kyprolis, devel-
oped by Onyx Pharmaceuticals) was approved for the treatment
of refractory multiple myeloma (Figures S3A and S3B available
online). Carfilzomib primarily targets the chymotrypsin-like sites
of the constitutive proteasomes, b5c, with five times the selec-
tivity over the immunoproteasome chymotrypsin-like subunit
b5i (IC50: 6 nM against b5c; 33 nM against b5i) (Demo et al.,
2007). Caspase-like and trypsin-like sites are inhibited less,
with IC50 values of 2400 and 3600 nM, respectively (Demo
et al., 2007). In contrast, the other FDA-approved proteasome in-
hibitor, bortezomib (Velcade), targets the chymotrypsin-like sites
of constitutive proteosomes and immunoproteasomes with
similar potency (IC50: 6 nM [b5c]; 7 nM [b5i]) (Demo et al.,
2007), and the epoxomicin analog PR-957 (Figure S3D) primarily
targets immunoproteosomes (IC50: 1036 nM [b5c]; 73 nM [b5i])
(Huber et al., 2012).
The crystal structure of constitutive proteosome has been
solved for a number of organisms with similarity to humans,
including Saccharomyces cerevisiae (yeast; Protein Data Bank
ID [PDB] 1RYP), Bos taurus (bovine; PDB 1IRU), and Mus
musculus (mouse; PDB 3UNE). To date, all crystal structure
complexes with proteasome inhibitors of the constitutive proteo-
some have been solved bound to the yeast proteasome. Theights reserved
Table 1. Data Collection and Refinement Statistics
Human 20S
Proteasome Carfilzomib Bound
Crystal Parameters
Space group P 21 P 21
Unit Cell
a (A˚) 119.2 172.0
b (A˚) 205.1 201.0
c (A˚) 163.1 225.6
b 106.4 107.9
Data Collection
Wavelength (A˚) 0.97918 0.97918
Resolution range (A˚) 50–2.6 (2.64–2.60) 50–2.9 (2.99–2.89)
No. of observations 621,008 1,177,627
No. of unique reflections 228,370 321,261
Redundancy 2.7 (2.5) 3.7 (3.4)
Completeness (%) 98.2 (91.8) 98.7 (91.7)
I/Is 14.7 (2.1) 9.1 (1.1)
Wilson B factor 52.54 72.68
Rmerge 6.9 (56.6) 11 (127.3)
Refinement (Phenix)
Resolution range (A˚) 33.5–2.59 33.5–2.89
Rwork 0.20 0.22
Rfree 0.24 0.25
No. of atoms 47,831 95,976
Protein 47,646 95,187
Ligands – 572
Water 185 217
Protein residues 6,286 12,572
Rmsd
Bond lengths (A˚) 0.004 0.004
Bond angles (o) 0.77 0.78
Ramachandran favored (%) 95 95
Average B factor (A˚2) 83.8 80.3
Highest-resolution shell values are given in parentheses.proteasome:epoxomicin complexwas reported forS. cerevisiae,
and the mouse immunoproteasome and constitutive protea-
somes have been reported bound with the b5i-specific epoxyke-
tone inhibitor PR-957. Neither the X-ray structure of the human
constitutive proteosome nor that of the proteasome:carfilzomib
complex has been reported.
Here, we present the crystal structure of the human constitu-
tive proteasome purified from red blood cells, in the presence
and absence of carfilzomib at 2.9 and 2.6 A˚ resolutions, respec-
tively. The structure of the proteasome:carfilzomib complex ex-
plains the different in vivo binding affinities of the drug for the
individual catalytic sites of the proteasome, at a high resolution.
Specificity for chymotrypsin-like subunits (b5) can be attributed
to van der Waals interactions in the S1, S3, and S4 specificity
pockets. Trypsin-like sites also show favorable van der Waals in-
teractions in the S3 and S4 pockets; however, a spacious S1
pocket may disfavor ligand binding and result in less selectivity
than in chymotrypsin-like sites. Caspase-like sites have a polarStructure 23, 41S1 pocket, which disfavors carfilzomib’s hydrophobic P1 leucyl
group, and His116 in the S4 pocket sterically blocks carfilzo-
mib’s P4 phenyl group. This results in a disordered N-terminus
of the drug, and likely contributes to the higher IC50 value than
in chymotrypsin-like sites. Comparison of our proteasome:carfil-
zomib complex with the mouse constitutive proteasome:PR-957
complex suggests that it is primarily PR-957’s P3 alanine and
lack of a P4 substituent that are contributing factors toward se-
lecting for immunoproteasome chymotrypsin-like sites and not
merely the structural rearrangements in the S1 pocket, as previ-
ously suggested. The data presented here will allow for the
design of carfilzomib analogs with either increased constitutive
or immunoproteasome selectivity, with implications for the treat-
ment of cancer and autoimmune diseases.
RESULTS AND DISCUSSION
Structure Determination of Human Constitutive 20S
Proteasome
The lack of immunoproteasomes in red blood cells allowed us to
purify the human 20S proteasome constitutive core particle to
high purity and remove any discrepancies in the structure due
to immunoproteasome subunits. Diffraction data from the pro-
teasome crystals extended to a maximum resolution of 2.6 A˚
and the crystals were in the space group P21 with one molecule
in the asymmetric unit. Molecular replacement with the bovine
constitutive proteosome (PDB 1IRU; Unno et al., 2002) was fol-
lowed by positional refinement and 2-fold noncrystallographic
symmetry (NCS) averaging. Refinement resulted in a final struc-
ture with Rwork and Rfree values of 0.20 and 0.24, respectively,
with root-mean-square deviation (rmsd) bond and angle values
of 0.004 A˚ and 0.77, respectively (Table 1).
For the carfilzomib bound structure, crystals were soakedwith
5 mM of the drug for 12 hr. Data were collected as described for
the apo crystals and resolution extended to 2.9 A˚. The space
group was P21; however, two molecules were in the asymmetric
unit. Refinement resulted in final Rwork and Rfree values of 0.22
and 0.25, respectively, with good stereochemistry. Electron
density maps depicted binding of carfilzomib in all four chymo-
trypsin-like (b5) and trypsin-like (b2) active sites in the asym-
metric unit and in three of the four caspase-like (b1) sites.
Architecture of the Human 20S Proteasome
The organization and overall topology of the human constitutive
proteasome subunits are conserved with the eukaryotic protea-
somes whose structures have been reported, including the
C-terminus of subunit b2, from residue Leu186 to Glu220, which
wraps around subunit b3 and forms an additional strand in its
antiparallel b sheet, S12 (Groll et al., 1997; Huber et al., 2012;
Unno et al., 2002) (Figure S1B). All seven distinct a and b sub-
units have the same general b sandwich architecture, which is
typical for N-terminal hydrolases (two antiparallel b sheets, sur-
rounded on either side by two or three a helices).
Superposition of individual catalytic b subunits of the human
constitutive proteasome with corresponding subunits of the
mouse constitutive proteasome indicates that they adopt very
similar folds (rmsd Ca atoms 0.38 A˚ for b1, 0.40 A˚ for b2, and
0.32 A˚ for b5), as does superposition with respective yeast cat-
alytic subunits (rmsd Ca atoms 1.5 A˚ for b1, 0.65 A˚ for b2, and8–424, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 419
Figure 1. Architecture of the Human 20S Proteasome and Carfilzo-
mib Binding
Subunits a4 and b4 have been removed for clarity. Carfilzomib is bound to all
six catalytic centers. Insets show surface representation of the proteasome
active sites with carfilzomib bound. The 2Fo  Fc map is scaled to 1s and
colored blue, Thr1 is colored black, and carfilzomib green. The red line
indicates C2 symmetry. See also Figure S1.1.6 A˚ for b5). This is to be expected, based on the high level of
amino acid sequence conservation (>95% with mouse). The en-
try gate to the central proteolytic chamber is closed by the
N-termini of the a subunits, which project into the pore of the a
ring, forming several layers (Figure S1). Superposition of the a
ring of the human proteasome with the a ring of the proteasomes
from yeast, bovine, and mouse, also illustrates high structural
conservation (rmsd Ca atoms a ring <0.59 A˚ for all a rings).
Substrate selectivity for the catalytic subunits is dictated by
the interaction of the substrate’s P1 side chain with the active
site’s S1 specificity pocket. Specifically, residue 45 at the base
of the S1 pocket aids in determining the three distinct cleavage
preferences. In subunit b5, the residues in the S1 pocket that
give rise to chymotrypsin-like activity are Ala20, Met45, Ala49,
and Cys52. Met45 protrudes into the pocket, 6.9 A˚ from Thr1,
allowing it to accommodate hydrophobic residues such as
alanine, valine, or tyrosine. The S1 pocket in subunit b1 is lined
with residues Thr20, Thr31, Thr35, Arg45, Ala49, Gln53, and
b2Asp120. Positively charged Arg45 at the base of the S1
pocket, 8.5 A˚ from Thr1, accommodates acidic residues, which
gives rise to the caspase-like substrate selectivity. Caspase-like
sites have also been reported to cleave after some hydrophobic
residues, thereby also contributing to the branched-chain amino420 Structure 23, 418–424, February 3, 2015 ª2015 Elsevier Ltd All racid preference activity of the proteasome and generation of
major histocompatibility complex class I ligands (Dick et al.,
1998; McCormack et al., 1998). Subunit b2 has trypsin-like activ-
ity, cleaving after arginine and lysine residues. The base of the S1
pocket contains Gly45 resulting in a depth of 12 A˚, a consider-
ably larger S1 pocket than chymotrypsin-like or caspase-like
sites. Residues Cys31, His35, Asp53, and b3Cys129 give the re-
gion an overall acidic character, leading to the preference for
basic residues.
Proteasome Inhibition by Carfilzomib
The difference electron densitymap for carfilzomib-soaked crys-
tals indicate that carfilzomib targeted all four chymotrypsin-like
and trypsin sites, and three of the four caspase-like sites in the
asymmetric unit; all through covalent binding to Thr1 (Figure 1).
Subunit b7 did not have carfilzomib bound; therefore, it remains
elusive as to whether it is an active subunit.
Carfilzomib modified Thr1 in each inhibited subunit via a dual
covalent adduct with its C-terminal epoxyketone. A morpholino
ring is formed with Thr1N and Thr1Og, which is consistent with
proteasome inhibitionbyotherepoxyketone inhibitors suchasep-
oxomicin (Groll et al., 2000) and PR-957 (Huber et al., 2012). The
N-terminal morpholino moiety of carfilzomib is not engaged in
any interactions with the protein in any of the catalytic sites. How-
ever, in chymotrypsin-like and trypsin-like sites the backbone of
carfilzomib is curved approximately 45 relative to caspase-like
sites. This change in orientation is due to a steric effect caused
by the side chains of b3Glu106 and b6Tyr107 in trypsin-like and
chymotrypsin-like binding regions, respectively, which force the
morpholino ring to turn toward b sheet S3 to avoid clashing.
The electron density map reveals an ordered water molecule
(NUK) located 3.5 A˚ from Ser130N in all three catalytic sites.
The water molecule forms a 3.0 A˚ hydrogen bonding interaction
with carfilzomib’s P1 carbonyl oxygen. The water molecule was
first described in the yeast proteasome crystal structure, and is
suggested to be involved in both intramolecular autolysis and
substrate proteolysis by mediating proton transfer between
Thr1Og and Thr1N (Groll et al., 1997).
The C-terminal end of carfilzomib completes an antiparallel b
sheet in each of the proteasome binding channels with the
conserved amino acids Thr21, Gly47, and Ala49 (Figures 2A,
S2A, and S2B). Although the residues that form the hydrogen
bonds are conserved in all three catalytic centers, the hydrogen
bonding distances differ between subunits. The hydrogen bonds
can be summarized for the caspase-like sites as follows: Thr21N
(3.3 A˚) and Thr21O (2.9 A˚) of b strand S3 on one side of the
binding pocket, and Gly47O (2.7 A˚) and Ala49N (3.4 A˚) from
the loop connecting S6 and H1 on the other side of the binding
pocket. The hydrogen bond distances are as follows: Thr21N
3.3 A˚, Thr21O 2.9 A˚, Gly47O 3.0 A˚, and Ala49N 2.7 A˚ in the
trypsin-like sites; and Thr21N 3.2 A˚, Thr21O 2.9 A˚, and Gly47O
2.7 A˚ in the chymotrypsin-like sites. A second water molecule
(WAT) found in the chymotrypsin-like site makes a 2.5 A˚
hydrogen bond with the P3 carbonyl oxygen of carfilzomib,
replacing the hydrogen bond from Ala49N and shortening
the hydrogen bond distance by 0.5 A˚. The water is also
hydrogen bridged with Ala49N (3.0 A˚), Ala50N (2.9 A˚), and
b6Asp125O d2 (3.2 A˚). The water molecule was reported in the
yeast:bortezomib crystal structure, but was not described inights reserved
Figure 2. Carfilzomib Binding to Chymo-
trypsin-Like Sites
(A) Stereoview of carfilzomib bound to the
chymotrypsin-like site. Carfilzomib is colored
green; hydrogen bonds are shown as black
dashed lines; water molecules are shown as red
spheres; T1 is colored black. See also Figures S2A
and S2B.
(B) Structural alignment of unbound (white) and
carfilzomib bound (wheat) chymotrypsin-like sites.
Carfilzomib is colored green; T1 is black; black
arrows indicate shifts of Met45, Ile35, b sheet S6,
and a helix H1.
(C) Carfilzomib interactions in the P3 and P4 po-
sitions of the chymotrypsin-like site of the human
constitutive proteosome. Proteasome is colored
wheat; carfilzomib is green; T1 is black.the mouse immunoproteasome or constitutive proteasome
complexes with the epoxyketone inhibitor PR-957; therefore,
whether it is important for chymotrypsin-like selectivity of inhib-
itors is ambiguous.
An additional hydrogen bond is found in the chymotrypsin-like
and trypsin-like sites, between Asp125O d2 of the adjoining sub-
unit (b6 and b3, respectively) and carfilzomib’s P3 peptide bond,
with distances of 3.2 and 2.7 A˚, respectively. This interaction is
missing in caspase-like sites, where the aspartate residue is re-
placed by Tyr114, which is flipped away from carfilzomib and
points into the S3 pocket (Figures 2A, S2A, and S2B).
Interactions of Carfilzomib with Proteasome
Specificity Pockets
A detailed evaluation of the active subunits in the presence and
absence of carfilzomib visualized the structural features that lead
to the drug’s chymotrypsin-like selectivity. In caspase-like sites,
the N-terminus of carfilzomib, beginning at the P4 phenyl group,
is not well defined in the electron density (Figure 1). ComparisonStructure 23, 418–424, February 3, 2015with chymotrypsin-like and trypsin-like
sites reveals that His116 of chain b7
acts to sterically block carfilzomib’s P4
phenyl group from entering the S4 pocket
of caspase-like sites. Structural align-
ment with either chymotrypsin-like or
trypsin-like subunits shows that the P4
substituent of carfilzomib is shifted up to
3.7 A˚ away from the S4 pocket. In addi-
tion, the P4 phenyl group of caspase-
like sites makes no interactions with the
protein. In contrast, chymotrypsin-like
and trypsin-like sites each have S4
pockets that favor the hydrophobic P4
phenyl group of carfilzomib. Van der
Waals interactions are made with the
side chains of b6Val127 (4.0 A˚) in chymo-
trypsin-like sites (Figure 2C) and b3Ile126
(3.8 A˚) and b3Ile127 (4.0 A˚) in trypsin-like
sites.
The P3 position of carfilzomib contains
leucine, which is able to make van derWaals interactions in each of the three distinct catalytic subunits.
In chymotrypsin-like sites, the S3 pocket has four hydrophobic
amino acid side chains that surround the P3 leucyl and make
van der Waals contacts as follows: Ala20 (3.9 A˚), Ala22 (4.4 A˚),
Ala27 (3.9 A˚), and the aliphatic side chain carbon of b6Asp125
(3.6 A˚) (Figure 2C). Caspase-like sites make van der Waals con-
tacts with the side chains of Ala27 (3.3 A˚), Thr20 (4.0 A˚), Thr22
(4.3 A˚), and the phenyl ring of b2Tyr114 (3.7 A˚). In trypsin-like
sites, the van der Waals interactions come from the side chains
of Ala27 (4.3 A˚), Ala20 (4.4 A˚), and the aliphatic carbon of Glu22.
The S2 pockets of all three active sites are able to accommo-
date the P2 phenylalanine moiety of carfilzomib and no contacts
are made with the protein. The crystal structure of bortezomib
bound to the yeast proteasome shows that its P2 phenylalanine
ring is flipped toward Thr1 in both the chymotrypsin-like and cas-
pase-like sites, and away from Thr1 in the trypsin-like sites (Groll
et al., 2006). In contrast, our proteasome:carfilzomib complex
shows that the phenyl ring is flipped away from Thr1 in all three
distinct catalytic centers. Carfilzomib’s P2 substituent assumesª2015 Elsevier Ltd All rights reserved 421
Figure 3. PR-957 Causes Structural Rear-
rangements Similar to Carfilzomib upon
Binding to Chymotrypsin-Like Sites of the
Constitutive Proteasome but Not the Immu-
noproteasome
(A) The unbound mouse constitutive proteasome
chymotrypsin-like site is colored cyan; the PR-957
bound structure is pink; PR-957 is yellow (PDB
3UNE for unbound structure and 3UNB for PR-957
bound structure). Structural rearrangements that
are also seen with the human proteasome:
carfilzomib complex are indicated with black
arrows.
(B) The unbound mouse immunoproteasome
chymotrypsin-like site is colored cyan and is
superimposed on the PR-957 bound im-
munoproteasome chymotrypsin-like site, which is
colored pink. PR-957 is colored yellow (PDB
3UNH for unbound structure and 3UNF for PR-957
bound structure). No structural rearrangements
are observed, indicated with black arrows.
(C) PR-957 bound to the mouse constitutive pro-
teasome following the same color scheme as in
(A). PR-957 has a P3 alanine and no P4 substitu-
ent, resulting in fewer van der Waals interactions
and, therefore, decreased selectivity for constitu-
tive chymotrypsin-like sites compared with carfil-
zomib (PDB 3UNB).the same orientation taken by the P2 methoxyphenyl substituent
of PR-957 in the mouse immunoproteasome and constitutive
proteasome structures (Huber et al., 2012).
The S1 pocket in caspase-like sites (b1) is positively charged
by the guanidinium group of Arg45 and therefore does not favor
the hydrophobic P1 leucyl group of carfilzomib. In trypsin-like
subunits, Gly45 results in a more spacious S1 pocket in compar-
ison with caspase-like and chymotrypsin-like subunits. Conse-
quently, the only favorable interactions made with the leucyl
group are van der Waals contacts with Ala49 (3.9 A˚) and Ala20
(4.1 A˚).
The S1 pocket of chymotrypsin-like subunits makes van der
Waals contacts with carfilzomib’s P1 leucyl from the side chains
of Ala49 (3.7 A˚), Val31 (4.5 A˚), Ala20 (3.5 A˚), and Met45 (4.3 A˚).
Structural alignment of unbound and carfilzomib bound protea-
some (rmsd Ca = 0.4 A˚) reveals that upon binding of carfilzomib,
the P1 leucyl group causes the side chain of Met45 to shift by
2.7 A˚ toward Ile35, which is then shifted by 1.7 A˚ (Figure 2B).
In contrast to caspase-like subunits where Arg45 is hydrogen
bonded and unable to accommodate the leucyl group, the
Met45 side chain is not stabilized by surrounding residues and
is therefore flexible. Upon shifting of the Met45 and Ile35 side
chains, conformational changes involving residues 34–72 are
also seen. This offsets b sheets S4 and S5 as well as a helix
H1 in comparison with the unbound structure (Figure 2B).
In summary, caspase-like sites disfavor carfilzomib binding
due to electrostatic and steric effects at the P1 and P4 positions,422 Structure 23, 418–424, February 3, 2015 ª2015 Elsevier Ltd All rights reservedrespectively, while chymotrypsin-like and
trypsin-like sites show similar hydrogen
bonding and Van der Waals interactions.
The most profound difference between
chymotrypsin-like and trypsin-like sitesis the size of the S1 pocket, and the number of van der Waals
contacts made with the P1 leucyl of carfilzomib. This may sug-
gest the importance of a properly stabilized P1 substituent for
modification of Thr1 by the epoxyketone pharmacophore.
Despite these seemingly minor differences, carfilzomib is nearly
1000-fold more potent toward chymotrypsin-like subunits. An
additional explanation may be accessibility. It is interesting to
note that the IC50 for trypsin-like sites of immunoproteasomes
is reduced to 620 nM (Screen et al., 2010), whichmay be a reflec-
tion of better accessibility in immunoproteasomes, considering
that active site substitutions between the two isoforms do not
appear to change the character of the binding region.
Carfilzomib Maintains Chymotrypsin-Like Selectivity,
Despite Structural Rearrangements
The residue and loop movements in the chymotrypsin-like
S1 pocket of our constitutive proteasome:carfilzomib complex
were also reported in the crystal structure of the mouse constitu-
tive proteasome:PR-957 complex but not in the mouse immuno-
proteasome:PR-957structure (Huber et al., 2012) (Figures 3Aand
3B). In the immunoproteasome chymotrypsin-like subunit, the
side chain of Met45 in the S1 pocket is stabilized by the aliphatic
side chain of the conserved aminoacid substitutionGln53, result-
ing in a larger S1 pocket than in constitutive chymotrypsin-like
sites. The shifts were suggested to be the cause for PR-957’s
selectivity for the immunoproteasome chymotrypsin-like site.
Carfilzomib is slightlymoreselective for constitutiveproteasomes
than for immunoproteasomes (IC50 6and34nM, respectively), yet
causes the same protein rearrangements. To investigate this
discrepancy,wecomparedour proteasome:carfilzomibstructure
with the mouse constitutive proteasome:PR-957 complex.
Themost notable differences reside at the P4 and P3 positions
of the two drugs. PR-957 is a tripeptide epoxyketone and is un-
able to make interactions with the S4 binding pocket (Figure 3C),
whereas carfilzomib makes van der Waals interactions with
b6Val127 (Figure 2C). In addition, PR-957 contains a P3 alanine,
as opposed to carfilzomib’s P3 leucyl group.While thismaintains
a hydrophobic nature, the distance of PR-957’s alanine to the
residue side chains in the S3 pocket is up to 1.9 A˚ greater
(Ala20) than those of carfilzomib’s P3 leucyl group. Taken
together, these results suggest that PR-957’s selectivity for im-
munoproteasomes is only partially explained by the larger S1
pocket. While it is the structural rearrangements in the S1 pocket
that initially lead to immunoproteasome selectivity, for energetic
reasons this can be compensated for by interactions in the S3
and S4 pockets.
These observations are further supported by the tripeptide
epoxyketone inhibitor ONX0912 (PR-047) (Figure S3C), which,
like PR-957, also contains a phenylalanine side chain at the P1
position. Based on previous suggestions, a phenylalanine at
the P1 position should favor binding to immunoproteasomes;
however, the reported IC50 values indicate that it is 2-fold more
selective for the constitutive chymotrypsin-like site (IC50 36 nM
[b5c]; 82 nM [b5i]) (Zhou et al., 2009). PR-047 contains amethoxy
group at the P3 position and is suitable for making van der Waals
interactions with the hydrophobic S3 pocket of chymotrypsin-
like subunits, thereby explaining the change in selectivity and
further highlighting the importance of the P3 substituent. Only
a structure of the proteasome:PR-047 complex could indicate
whether the N-terminal 2-methyl-1,3-thiazole cap is associated
with the S4 pocket, which would also add favorable hydrophobic
interactions leading to the constitutive proteasome chymo-
trypsin-like preference.
Structural Basis for Carfilzomib’s Selectivity for
Constitutive Proteasome Chymotrypsin-Like Subunits
To investigate why carfilzomib’s IC50 is lower for binding to the
chymotrypsin-like subunits of constitutive proteasomes over im-
munoproteasomes, we structurally aligned the carfilzomib
bound chymotrypsin-like subunit (b5) of our structure, with the
mouse immunoproteasome chymotrypsin-like subunit (b5i)
(rmsd Ca = 0.59 A˚). The amino acid sequence similarity between
the two subunits is 92% and they share five conserved
amino acid substitutions in the substrate binding region. The
conserved substitution Gly48Cys places the polar cysteine
side chain 3.2 A˚ from carfilzomib’s P4 phenyl group. In addition,
the conserved substitution Ala27Ser places the polar side chain
of serine within 3.3 A˚ of the P3 leucyl group. Given the impor-
tance of the P3 and P4 positions to the IC50 value, as indicated
previously for PR-957, it is possible that these minor changes
could account for the nearly 6-fold increase in the IC50 value
between immunoproteasome and constitutive proteasome,
respectively.
The proteasome remains an attractive target for antineo-
plastic drugs, and the elucidation of the X-ray structure of the
human constitutive proteosome provides the details necessaryStructure 23, 41for it to serve as a useful tool in future drug development. The
use of carfilzomib in the clinic makes it imperative that the
binding mode be well understood at the molecular level.
The structures reported here will assist in the development of
constitutive and immunoproteasome specific inhibitors, with
therapeutic potential in cancer as well as autoimmune and
neurodegenerative diseases.
EXPERIMENTAL PROCEDURES
Protein Purification
The constitutive 20S proteasome was purified from human erythrocytes. Red
blood cells, isolated from 500 ml of whole blood and suspended in saline so-
lution, were obtained from Gulf Coast Regional Blood Center, College Station,
TX. Cells were pelleted then resuspended in lysing buffer (20 mM Tris [pH 7.0],
50 mM MgCl2, 1 mM EDTA) and protein extracted with a French press. After
centrifuging the lysate, the supernatant was loaded onto a HiTrap QHP anion
exchange column (GE Healthcare) pre-equilibrated with buffer A (10 mM Tris
[pH 7.5], 1 mM EDTA, 350 mM NaCl). After washing the column with at least
five column volumes of buffer A, column bound protein was eluted with a
gradient of buffer B (0%–100%) (10 mM Tris [pH 7.5], 1 mM EDTA, 700 mM
NaCl). Fractions containing proteasome were diluted 10-fold in buffer C
(10mMTris [pH 7.5], 1mMEDTA), then ammonium sulfate was added to a final
concentration of 40% saturation to the protein while stirring at 18C. The
solution was centrifuged and the supernatant loaded onto a HiTrap Phenyl
Sepharose FF column (GE Healthcare), pre-equilibrated with buffer D
(10 mM Tris [pH 7.5], 1 mM EDTA, 1.2 M ammonium sulfate). The column
was washed with five column volumes of buffer D, then column bound protein
was eluted with a gradient of buffer C (0%–100%). Fractions containing pro-
teasome were pooled and dialyzed against buffer C overnight then concen-
trated to 30 mg/ml for crystallization trials.
Crystallization
Proteasome crystals were produced by hanging drop vapor diffusion using a
1:1 ratio of protein solution (30 mg/ml, 10 mM Tris [pH 7.5], 1 mM EDTA)
and crystallization buffer (0.2 M sodium formate, 40% MPD) at 16C. Crystals
appeared in 7–10 days and grew to a maximum size of 0.3 mm. For inhibitor
bound structures, proteasome crystals were soaked for 12 hr with carfilzomib
at a final concentration of 5 mM in crystallization buffer. Crystals were soaked
in cryoprotecting buffer (30% MPD, 0.2 M sodium formate) and flash frozen
with liquid nitrogen prior to data collection. Data were collected using synchro-
tron radiation at the Advanced Photon Source (Argonne National Laboratory,
Lemont, IL) with l = 0.97918 A˚, at beamlines 23iD and 19iD.
Data Collection and Structure Determination
X-Ray intensities for both apo and carfilzomib bound structures were evalu-
ated using HKL3000. Calculations of theMatthews coefficient gave an approx-
imate solvent content of 50%, assuming one constitutive proteosome in the
asymmetric unit for native crystals, and two constitutive proteosomes per
asymmetric unit for carfilzomib bound crystals. Both structures were solved
by molecular replacement Phenix Phaser-MR using the coordinates of the
constitutive proteosome from Bos taurus (PDB 1IRU) as a starting model.
Refinement with Phenix led to Rwork and Rfree values of 0.20 and 0.24, respec-
tively, for the apo structure, and 0.22 and 0.25, respectively, for the carfilzomib
bound structure. Bonds and angles were also good, with values of 0.004 A˚ and
0.77, respectively, for the apo structure, and 0.004 A˚ and 0.78, respectively,
for the carfilzomib bound structure. Carfilzomib was generated using
PRODRG, and fit into the jFo  Fcj density manually in COOT. Coordinates
for finalized structures were confirmed to have good stereochemistry from
the Ramachandran plot (Table 1).
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